Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

Journal of Clinical Oncology

Volumn 29, Issue 17, 2011, Pages 2416-2423

  Imhof, Anna ^a   Brunner, Philippe ^a   Marincek, Nicolas ^a   Briel, Matthias ^a,c   Schindler, Christian ^b   Rasch, Helmut ^a   Mäcke, Helmut R ^a   Rochlitz, Christoph ^a   Müller Brand, Jan ^a   Walter, Martin A ^a,d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; CREATININE; INDIUM 111; TUMOR MARKER; UNCLASSIFIED DRUG; YTTRIUM 90;

ACTH SECRETING ADENOMA; ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ANEMIA; APPENDIX CANCER; APPENDIX CARCINOID; ARTICLE; BONE METASTASIS; BRONCHUS CARCINOID; CANCER SURVIVAL; CARCINOID; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DISEASE CONTROL; DISEASE COURSE; DISEASE DURATION; DRUG DISTRIBUTION; DRUG FATALITY; DRUG SAFETY; DUODENAL ULCER BLEEDING; ESOPHAGUS CANCER; ESOPHAGUS CARCINOID; FEMALE; FOLLOW UP; GASTRINOMA; GLOMERULUS FILTRATION RATE; GLUCAGONOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITALIZATION; HUMAN; HYPOPHYSIS TUMOR; INSULINOMA; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; KLATSKIN TUMOR; LARGE BOWEL CARCINOID; LARGE INTESTINE CANCER; LEUKOPENIA; LIVER METASTASIS; LIVER TUMOR; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MERKEL CELL TUMOR; METASTASIS; MULTIPLE CYCLE TREATMENT; MYELOID LEUKEMIA; MYELOPROLIFERATIVE DISORDER; NEPHROTOXICITY; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OVARY TUMOR; OVERALL SURVIVAL; PARAGANGLIOMA; PHASE 2 CLINICAL TRIAL; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROSTATE TUMOR; SCHOOL CHILD; SCINTIGRAPHY; SINGLE DRUG DOSE; SMALL BOWEL CARCINOID; SMALL INTESTINE CANCER; STOMACH CARCINOID; THROMBOCYTOPENIA; THYMUS CANCER; THYMUS CARCINOID; THYROID CANCER; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR LYSIS SYNDROME; TUMOR VOLUME; UTERINE CERVIX CANCER; VIPOMA; WHOLE BODY IMAGING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; OCTREOTIDE; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 79959208861     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.7873     Document Type: Article

References (35)

1. Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427, 2003
2. Oberg K: Cancer: Antitumor effects of octreotide LAR, a somatostatin analog. Nat Rev Endocrinol 6:188-189, 2010
3. Rinke A, Müller HH, Schade-Brittinger C, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 27:4656-4663, 2009
4. Krenning EP, Bakker WH, Breeman WA, et al: Localisation of endocrine-related tumours with radio-iodinated analogue of somatostatin. Lancet 1:242-244, 1989
5. Otte A, Mueller-Brand J, Dellas S, et al: Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351:417-418, 1998 (Pubitemid 28064170)
6. Waldherr C, Pless M, Maecke HR, et al: The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 12:941-945, 2001
7. Iten F, Müller B, Schindler C, et al: Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: A phase II clinical trial. Clin Cancer Res 13:6696-6702, 2007
8. Waldherr C, Pless M, Maecke HR, et al: Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43:610-616, 2002 (Pubitemid 34507110)
9. Otte A, Jermann E, Behe M, et al: DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 24:792-795, 1997 (Pubitemid 27356860)
10. Otte A, Herrmann R, Heppeler A, et al: Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 26:1439-1447, 1999 (Pubitemid 29515605)
11. Klahr S, Levey AS, Beck GJ, et al: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease: Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877-884, 1994 (Pubitemid 24094966)
12. Putter H, Fiocco M, Geskus RB: Tutorial in biostatistics: Competing risks and multi-state models. Stat Med 26:2389-2430, 2007 (Pubitemid 46730255)
13. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
15. Reubi JC, Hacki WH, Lamberts SW: Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab 65:1127-1134, 1987 (Pubitemid 18026846)
16. Gery B, Roussel A, Valla A: Usefulness of radiotherapy in the treatment of advanced gastrinomas. Radiother Oncol 27:259-260, 1993 (Pubitemid 23270053)
17. Papotti M, Croce S, Macrì L, et al: Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol 9:47-57, 2000 (Pubitemid 30131962)
18. Yao JC, Hassan M, Phan A, et al: One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063-3072, 2008
19. Oberg K: Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 12:S111-S114, 2001 (suppl 2)
20. Kulke MH, Lenz HJ, Meropol NJ, et al: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403-3410, 2008
21. Yao JC, Lombard-Bohas C, Baudin E, et al: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol 28:69-76, 2010
22. Kwekkeboom DJ, de Herder WW, Kam BL, et al: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 26:2124-2130, 2008
23. Teunissen JJ, Kwekkeboom DJ, Krenning EP: Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Clin Oncol 22:2724-2729, 2004 (Pubitemid 41103761)
24. Cybulla M, Weiner SM, Otte A: End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med 28:1552-1554, 2001
25. Asnacios A, Courbon F, Rochaix P, et al: Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: New prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 26:963-970, 2008 (Pubitemid 351398091)
26. Iten F, Muller B, Schindler C, et al: [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: Long-term results of a phase 2 clinical trial. Cancer 115:2052-2062, 2009
27. Buchmann I, Henze M, Engelbrecht S, et al: Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34:1617-1626, 2007 (Pubitemid 47476920)
28. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
29. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
30. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
31. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
32. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
33. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 (Pubitemid 46021510)
34. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981 (Pubitemid 11167383)
35. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009